The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The elections, while a landmark of democratic transformation, were also shaped significantly by external influences particularly from West Germany. Writer Michael Schneider was among those who criticised what he viewed as overwhelming interference by West German politicians and institutions. In his work, he described the campaign environment as one saturated with West German personalities, party activists and messaging. West German political parties, especially its branches of the Christian Democratic Union (CDU) and Social Democratic Party (SPD), sent campaigners and resources across the border to bolster their East German affiliates. According to Schneider, taxpayer funds from West Germany were used to support this mobilisation, raising questions about the balance of influence and the fairness of the electoral playing field. Civil rights activist and co-founder of the New Forum, Jens Reich, echoed these concerns from the perspective of the East German opposition. Speaking two decades after the vote, he reflected that the entire West German political apparatus had been transplanted into the East, overwhelming grassroots democratic movements that had played a key role in the Peaceful Revolution. In his words, "The Bonn hippopotamus came in such a mass that you were simply helpless." Reich observed that the election campaign bore little resemblance to a homegrown democratic process and instead felt like a western-style election exported wholesale into a fragile new democracy.
== Usage == In the United States, the Environmental Protection Agency (EPA) is responsible for regulating pesticides under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), the Food Quality Protection Act (FQPA) and the Pesticide Registration Improvement Act (PRIA). A pesticide can only be used legally according to the directions on the label that is included at the time of the sale of the pesticide. The purpose of the label is "to provide clear directions for effective product performance while minimizing risks to human health and the environment". A label is a legally binding document that mandates how the pesticide can and must be used and failure to follow the label as written when using the pesticide is a federal offence. Acifluorfen sodium is normally applied postemergence (when weeds are visible in the crop).
Cape Verde, Curaçao, Jordan, and Uzbekistan made their World Cup debuts. Qatar qualified for the tournament through qualification for the first time, as its only previous appearance was as host in 2022. DR Congo and Haiti returned to the tournament after appearing in their only previous tournament in 1974. Iraq returned to the tournament after appearing in its only previous tournament in 1986. Austria, Norway, and Scotland returned to the tournament after last appearing in 1998. Four-time champion Italy failed to qualify after losing the European playoff final to Bosnia and Herzegovina on penalties, becoming the first former champion to miss three consecutive World Cups; as in 2018 and 2022, Italy was the only former champion that did not qualify. With a FIFA Men's World Ranking of 12, Italy was also the highest-ranking team that did not qualify. The qualified teams, listed by region, with numbers in parentheses indicating final positions in the FIFA Men's World Ranking before the tournament were:
RNA-editing processes show great molecular diversity, and some appear to be evolutionarily recent acquisitions that arose independently. The diversity of RNA editing phenomena includes nucleobase modifications such as cytidine (C) to uridine (U) and adenosine (A) to inosine (I) deaminations, as well as non-template nucleotide additions and insertions. RNA editing in mRNAs effectively alters the amino acid sequence of the encoded protein so that it differs from that predicted by the genomic DNA sequence.
Increased appetite, weight gain, nausea, malaise, Increased risk of infection Cardiovascular events Dermatological effects including reddening of the face, bruising/skin discoloration, impaired wound healing, skin atrophy, skin rash, edema, and abnormal hair growth Hyperglycemia; patients with diabetes may need increased insulin or diabetic therapies Menstrual abnormalities Lower response to hormones, especially during stressful instances such as surgery or illness Change in electrolytes: rise in blood pressure, increased sodium and low potassium, leading to alkalosis Gastrointestinal system effects: swelling of the stomach lining, reversible increase in liver enzymes, and risk of stomach ulcers Muscular and skeletal abnormalities, such as muscle weakness/muscle loss, osteoporosis (see steroid-induced osteoporosis), long bone fractures, tendon rupture, and back fractures Neurological effects, including involuntary movements (convulsions), headaches, and vertigo Psychosocial behavioral and emotional disturbances with aggression being one of the most common cognitive symptoms, especially with oral use. Nasal septum perforation and bowel perforation (in some pathologic conditions). Discontinuing prednisolone after long-term or high-dose use can lead to adrenal insufficiency. Mania and hypomania are known possible side effects of prednisolone.
Sources: en.wikipedia.org
=== February === 9 February – The Scottish Prison Service concludes its review of accommodating transgender prisoners, and recommends that transgender prisoners initially be accommodated according to their sex at birth while an individual assessment is carried out. 10 February – Following a legal challenge by lap dance performers and club owners, a ban on lap dancing clubs in Edinburgh, scheduled to come into force in April, is overturned by Edinburgh's Court of Session after it finds Edinburgh City Council acted illegally by voting to limit the number of sexual entertainment venues in the city from four to zero. 15 February – Nicola Sturgeon announces her resignation as First Minister of Scotland and Leader of the Scottish National Party after eight years in the role; she will stay on until her successor has been elected. 16 February – Deputy First Minister John Swinney rules himself out of the SNP leadership contest. 17 February – The Royal College of Nursing recommends its members accept a new pay offer of 6.5%. The offer from the Scottish Government also includes changes to conditions. 19 February Scottish Health Secretary Humza Yousaf and former Minister for Community Safety Ash Regan become the first two candidates to announce they will stand in the Scottish National Party leadership election. Keith Brown, the SNP's depute leader, Neil Gray, the Minister for International Development, and Màiri McAllan, the Environment Minister, all rule themselves out of the contest.
=== Aircraft === C-4, the US Army designation of the Ford Trimotor AEG C.IV, a German World War I reconnaissance aircraft AGO C.IV, a 1917 German reconnaissance aircraft C-4 Academe, the military version of Gulfstream I twin turboprop business aircraft C-4 Argonaut, a Canadair aircraft derived from the Douglas DC-4 Cierva C.4, a 1922 Spanish experimental autogyro DFW C.IV, a 1916 German reconnaissance aircraft Flight Design C4, a four-seat light aircraft Fokker C.IV, a 1923 Dutch two-seat reconnaissance aircraft Rumpler C.IV, a 1917 German single-engine, two-seater reconnaissance biplane
== Treatment == In November 2020, the U.S. Food and Drug Administration approved lonafarnib, which helps prevent buildup of defective progerin and similar proteins. A clinical trial in 2018 points to significantly lower mortality rates – treatment with lonafarnib alone compared with no treatment (3.7% vs. 33.3%) – at a median post-trial follow-up time span of 2.2 years. The drug, given orphan drug status and Pediatric Disease Priority Review Voucher, is taken twice daily in the form of capsules and may cost US$650,000 per year, making it prohibitive for the vast majority of families. It is unclear how it will be covered by health insurance in the United States. Common side effects of the drug include "nausea, vomiting, diarrhea, infections, decreased appetite, and fatigue". Other treatment options have focused on reducing complications (such as cardiovascular disease) with coronary artery bypass surgery and low-dose acetylsalicylic acid. Growth hormone treatment has been attempted. The use of Morpholinos has also been attempted in mice and cell cultures in order to reduce progerin production. Antisense Morpholino oligonucleotides specifically directed against the mutated exon 11–exon 12 junction in the mutated pre-mRNAs were used. A type of anticancer drug, the farnesyltransferase inhibitors (FTIs), has been proposed, but their use has been mostly limited to animal models. A Phase II clinical trial using the FTI lonafarnib began in May 2007. In studies on the cells another anti-cancer drug, rapamycin, caused removal of progerin from the nuclear membrane through autophagy.
Flame ionization detector which uses ionizing flame to detect most hydrocarbon molecules Flame photometric detector which uses atomizing flame to get light emitted from specific elements to detect and quantify them Nitrogen Phosphorus Detector a thermionic detector with photometeric detection, sensitive specifically to nitrogen and phosphorus hydrocarbons Atomic-emission detector is a hyphenation between gas chromatography and atomic emission spectrophotometer for detection of elements. In all types of chromatography:
==== Site shaving ==== Before branding, the site of the brand must be shaved very closely to the skin. The site should also be shaved with at least the bottom edge as square as possible. This assists the worker when placing the brand and helps prevent it from dislodging on animals with thick coats. The excellent insulating properties of hair make a close shave critically important for achieving an even brand. Shaving permits a close interface between brand and flesh. Specialized clipper blades and heads have been designed for cryogenic branding and are made to provide as close a shave as possible. Once shaved, the area to be branded is soaked with alcohol to disinfect the animal's skin.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.